FDA recall, , Low risk
American Red Cross Blood Svcs Red Blood Cells, Leukocytes Reduced
Red Blood Cells, Leukocytes Reduced may have exceeded the acceptable collection volume.
American Red Cross Blood Svcs began this recall on Oct 7, 2025. FDA posted it on Oct 27, 2026, the day the recall ended.
Summary by Recall Canary from the FDA notice
What happened
American Red Cross Blood Svcs, located in Durham, North Carolina, voluntarily initiated a recall of Red Blood Cells, Leukocytes Reduced. The agency stated that these products were prepared from whole blood which may have exceeded the acceptable collection volume, and were distributed in North Carolina. The recall began on October 7, 2025, and was added to the FDA's Enforcement Report on October 27, 2026.
Customers were told by telephone. The FDA classified the recall on October 27, 2026, and it was included in the FDA's weekly enforcement report on November 4, 2026.
What to do
Biologics such as blood, tissue and vaccines are usually given by hospitals and clinics. If you had a transfusion, transplant, infusion or vaccine, ask the place that treated you whether this product was used. If they contact you, follow their advice.
What was recalled
Hospitals, clinics and blood banks match these details against their records.
Red Blood Cells, Leukocytes Reduced
- Unit number
- W181225299213008
Recall details
- Posted by FDA
- Recall began
- Status
- Ended Oct 27, 2026
- Weekly archive
- Listed the week of Oct 26, 2026
- Distributed to
- Recalled by
- American Red Cross Blood SvcsDurham, North Carolina
- Hazard
- Quality testing problem
- Risk
Low risk
Its use is unlikely to cause health problems.
FDA Class III recall · How risk is rated
- FDA event number
- 100024
- Recall number
- B-0013-2027
- Recall type
- Voluntary: Firm initiated
- How the company first told customers
- Telephone
All recalls from American Red Cross Blood Svcs
Timeline
FDA's Enforcement Report is its public list of recalls; FDA posts a recall by adding it there.
American Red Cross Blood Svcs began the recall
FDA posted the recall to its Enforcement Report, rated it Class III (low risk) and closed it
Added to Recall Canary
Summary updated